What Sorafenat is?
Sorafenib is a kinase inhibitor, indicated for the treatment of:
- Hepatocellular Carcinoma: an advanced primary Liver cancer.
- Renal Cell Carcinoma: a primary kidney cancer.
- Also, it is used in the patient with recurrent, progressive and metastatic differentiated thyroid carcinoma refractory to radioactive iodine treatment.
What Sorafenib Tosylate is?
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.